(vianews) - the market ended the session with erytech pharma (eryp.pa) rising 15.36% to €0.89 on monday while cac 40 jumped 1.51% to €7,295.55.
erytech pharma's last close was €0.77, 65.86% below its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-3.99.
earnings before interest, taxes, depreciation, and amortization
erytech pharma's ebitda is 7.45.
yearly top and bottom value
erytech pharma's stock is valued at €0.89 at 21:32 est, way below its 52-week high of €2.26 and way above its 52-week low of €0.29.
revenue growth
year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2m for the twelve trailing months.
more news about erytech pharma (eryp.pa).